Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
AstraZeneca
Sotio Biotech Inc.
Pfizer
Pfizer
Erasca, Inc.
Arvinas Inc.
xCures
Degron Therapeutics Co.
Bayer
Actym Therapeutics, Inc.
Ikena Oncology
Sensei Biotherapeutics, Inc.
Theratechnologies
Xynomic Pharmaceuticals, Inc.
Taproot Health
VitaMed Research LLC
Salubris Biotherapeutics Inc
ABM Therapeutics Corporation
Hoffmann-La Roche
Genmab
Kineta Inc.
MacroGenics
Fore Biotherapeutics
Lumos Pharma
Celgene
Celgene
Novartis
Calando Pharmaceuticals
Mannkind Corporation